32.91
0.15 (0.46%)
| Previous Close | 32.76 |
| Open | 33.00 |
| Volume | 1,307,834 |
| Avg. Volume (3M) | 1,172,303 |
| Market Cap | 3,121,849,088 |
| Price / Sales | 13.14 |
| Price / Book | 8.34 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Diluted EPS (TTM) | -2.47 |
| Total Debt/Equity (MRQ) | 17.67% |
| Current Ratio (MRQ) | 9.61 |
| Operating Cash Flow (TTM) | -200.95 M |
| Levered Free Cash Flow (TTM) | -111.55 M |
| Return on Assets (TTM) | -40.09% |
| Return on Equity (TTM) | -82.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Scholar Rock Holding Corporatio | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.00 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.87% |
| % Held by Institutions | 116.34% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |